<qa>  What is the goal of this research?The goal of this research is to build an index of risk for estimating an individuals risk of developing osteonecrosis of the jaw ONJ. The bisphosphonates are an important supportive therapy in the care of patients with metastatic bone disease; they are able to prevent catastrophic events such as fracture and spinal cord compression. However, ONJ has been associated with the use of the bisphosphonates and ONJ carries significant morbidity. Presently, there are insufficient data to calculate the ONJ risk benefit ratio of bisphosphonate use. An ONJ risk assessment tool would improve both the oncologists and the dental health professional the ability to anticipate and potentially mitigate oral toxicities from bisphosphonate therapy. 